Press Releases

Press Releases
Date Title and Summary View
Jan 4, 2011 BOUDRY, Switzerland, Jan 04, 2011 (BUSINESS WIRE) --Celgene International Sàrl (NASDAQ: CELG) announced regulatory submissions for its blood cancer therapies REVLIMID (lenalidomide) and ISTODAX (romidepsin). The company submitted a Marketing Authorisation Application (MAA) for the app...
Dec 30, 2010 SUMMIT, N.J., Dec 30, 2010 (BUSINESS WIRE) -- Celgene Corporation (NASDAQ: CELG) today announced its presentations at two upcoming investor conferences will be webcast live and will be available in the investor relations section of the company's Web site at www.celgene.com. Celgene management w...
Dec 13, 2010 SUMMIT, N.J., Dec 13, 2010 (BUSINESS WIRE) -- Celgene Corporation (NASDAQ: CELG) today announced its presentation at the 2010 Deutsche Bank BioFEST on Wednesday, December 15, 2010 at 8:30 a.m. ET will be webcast live and will be available in the investor relations section of the company's Web site at www.celgene.com. Celgene manag...
Dec 7, 2010 BOUDRY, Switzerland, Dec 07, 2010 (BUSINESS WIRE) -- Celgene International Sàrl (NASDAQ: CELG)today announced the results of a comparative study evaluating the impact of REVLIMID® (lenalidomide) on the risk of progression to acute myeloid leukaemia (AML) in patients with low/int-1 risk myelody...
Dec 7, 2010 BOUDRY, Switzerland, Dec 07, 2010 (BUSINESS WIRE) -- Celgene International Sàrl (NASDAQ: CELG)today announced updated results from a retrospective analysis of a randomised, international phase III study of REVLIMID® (lenalidomide) for the treatment of patients with low/int-1 risk myelodysplast...
Dec 7, 2010 BOUDRY, Switzerland, Dec 07, 2010 (BUSINESS WIRE) -- Celgene International Sàrl (NASDAQ: CELG) announced that clinical data from two investigational studies evaluating the combination of REVLIMID® (lenalidomide) plus rituximab in indolent non-Hodgkin's lymphoma (NHL) were presented at the 52nd Annual Meeting of the American ...
Dec 6, 2010 BOUDRY, Switzerland, Dec 06, 2010 (BUSINESS WIRE) --Celgene International Sàrl (NASDAQ: CELG) announced that data from the planned second interim analysis (median follow-up of 21 months) of a phase III, randomised, double-blind study of continuous REVLIMID® ...
Dec 6, 2010 BOUDRY, Switzerland, Dec 06, 2010 (BUSINESS WIRE) --Celgene International Sàrl (Nasdaq:CELG) today announced that data from a randomised clinical study conducted by the Eastern Cooperative Oncology Group (ECOG) were presented at the 52nd Annual Meeting of the American Society of Hematology comparing...
Dec 6, 2010 BOUDRY, Switzerland, Dec 06, 2010 (BUSINESS WIRE) -- Celgene International Sàrl (NASDAQ: CELG) today announced that updated data from an Intergroupe Francophone du Myelome clinical study under the sponsorship of the University Hospital of Toulouse were presented at the 52nd Annual Meeting of the American Society of Hematology....
Dec 6, 2010 BOUDRY, Switzerland, Dec 06, 2010 (BUSINESS WIRE) -- Celgene International Sàrl (NASDAQ: CELG) today announced that its next IMiD® compound, pomalidomide, was evaluated in three separate investigational trials of patients with multiple myeloma who were relapsed or refractory after prior treatm...
FirstPrevious ...
43
... NextLast
Add to Briefcase = add release to Briefcase